NOBLEOAK LIFE LIMITED (NOL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NOL

NOL - NOBLEOAK LIFE LIMITED

FNArena Sector : Insurance
Year End: June
GICS Industry Group : Insurance
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.35

05 Mar
2026

-0.022

OPEN

$1.35

-1.60%

HIGH

$1.40

30,831

LOW

$1.35

OTHER COMPANIES IN THE SAME SECTOR
AUB . CVW . FCL . GDG . HLI . IAG . MPL . NHF . QBE . SDF . SUN . TWR .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx8.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx476.4 M
Book Value Per Share xxxxxxxxxxxxxxx95.8
Net Operating Cash Flow xxxxxxxxxxxxxxx58.7 M
Net Profit Margin xxxxxxxxxxxxxxx1.49 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.88 %
Return on Invested Capital xxxxxxxxxxxxxxx8.43 %
Return on Assets xxxxxxxxxxxxxxx1.38 %
Return on Equity xxxxxxxxxxxxxxx8.88 %
Return on Total Capital xxxxxxxxxxxxxxx18.12 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx58.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx86 M
Price To Book Value xxxxxxxxxxxxxxx1.59

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.02 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx100 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx252 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

02/03/2026

1

Buy, High Risk

$2.85

111.11%

NobleOak Life's interim in-force premiums rose 19% to $505m, in line with Shaw and Partners' estimate, while underlying profit increased 11% to $9.6m, slightly below the broker's forecast.

Market share improved to 4.4% of in-force premiums and 13.8% of new business, highlights the analyst, with lapse rates -2.8ppts below the industry.

FY26 guidance is for at least 15% premium growth and profit growth of at least 10% was also reaffirmed.

Shaw expects further share gains amid industry consolidation and cites NobleOak Life's strong capital position with a 174% capital adequacy multiple.

Buy, High Risk. Target unchanged at $2.85.

FORECAST
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 21.70 cents.
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 23.40 cents.

NOL STOCK CHART